Non pharmacological interventions and non-fentanyl pharmacological treatments for breakthrough cancer pain: a systematic and critical review

Publication date: Available online 23 December 2017
Source:Critical Reviews in Oncology/Hematology
Author(s): Sebastiano Mercadante
Background: Oral opioids or other pharmacological or non-pharmacological interventions are often suggested in the management of breakthrough cancer pain (BTcP). The aim of this systematic and critical review was to analyse and critically comment the evidence of any non-fentanyl therapies proposed for BTcP.MethodsA systematic literature search was carried out to find studies providing clinical data on any treatment excluding fentanyl products.ResultsNo data exist about the use of oral opioids. Some information is available on parenteral morphine in a large sample of patients and episodes of BTcP. For other treatments, including methadone, nitrous oxide, anti-inflammatory drugs, samarium, and gabapentin the existing data, observational and obtained in a small number of patients do not provide useful information to be generalized. Only ketamine, a drug difficult to use for many physicians, particularly in determined setting, provided some evidence according a randomized controlled double-blind study.ConclusionsRecommendations suggesting the use of oral opioids or other pharmacological and non-pharmacologic interventions for BTcP, are not based on any, even minimal evidence. These treatments are worthwhile of further investigation, particularly in determined conditions that should fit the pharmacokinetics of oral opioids.



http://ift.tt/2znYBcg